絞り込み

16525

広告

ウマが人の行動を認識するのは「声」と「表情」の関連から (NHK)

移動の足などとして数千年前から家畜化が進んだウマは、人の声と表情の2つを関連づけて人の行動を認識していることが北海道大学などの実験でわかりました。身近な動物が人...

  1. 医療保険より100倍マシ! 学資保険の選...
  2. 食べられない高齢者にはこう介入する
  3. 血友病Aに週1回皮下注射の抗体医薬登場
  4. 39歳女性。胃痛、胸焼け

ニュース一覧

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification.

著者 Meedendorp AD , Ter Elst A , 't Hart NA , Groen HJM , Schuuring E , van der Wekken AJ
Front Oncol.2018 ; 8():176.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (20view , 0users)

Full Text Sources

Miscellaneous

A 62-year-old man was referred to our university hospital for treatment of advanced adenocarcinoma of the lung after disease progression on two lines of EGFR TKI and one line of chemotherapy. Fluorescent hybridization analysis upon progression showed an amplification. At our weekly Molecular Tumor Board (MTB), a decision was made to treat this patient with afatinib, which resulted in a partial response. However, progression was observed with a facial nerve paresis due to a metastasis in the skull. A biopsy of a location in the thorax revealed the presence of an EGFR-T790M mutation associated with acquired resistance, after which treatment with osimertinib was started. After 6 months, disease progression was observed, and a new biopsy was taken from the pelvic bone, which revealed the original amplification of together with the EGFR-L858R mutation, the EGFR-T790M mutation was not detected. The MTB decided to treat the patient with trastuzumab/paclitaxel. A partial response was observed in different bone lesions, while the skull metastasis with ingrowth in the brain remained stable for 6 months. Because of progression of the bone metastases after 6 months, a biopsy of a lesion in the thorax wall was taken. In this lesion, the EGFR-T790M mutation could be detected again. The MTB advised to start treatment with a combination of osimertinib and afatinib. This resulted in an impressive clinical improvement and a partial response of the bone metastases on the most recent 18-fluorodeoxyglucose positron emission tomography and computer tomography-scan. In conclusion, adjusting treatment to the mutational make-up of the tumor is a great challenge. For optimal treatment response multiple biopsies and re-biopsy upon progression are imperative. As more genes are investigated, treatment decision becomes increasingly difficult, therefore, expert opinions from an MTB is essential.
PMID: 29872644 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード